June 3, 1998 |
I-Flow Corp. said Tuesday it received approval from the U.S. Food and Drug Administration to market its disposable PainBuster infusion pain management kit for orthopedic surgery patients. I-Flow said the system uses Bupivacaine HC1, a nonnarcotic drug, avoiding the side effects of narcotics like morphine. The drug is infused directly into a patient 24 to 48 hours after an operation, The Lake Forest company's stock climbed 13%, or 25 cents, to $2.13 a share.
November 8, 1992
I-Flow Corp., a manufacturer of medical devices, reported a third-quarter loss of $812,000, or 14 cents a share, compared with a loss of $812,000, or 26 cents a share, for the same period a year earlier. Revenue rose to $615,000 from $114,000. For the first three quarters of 1992, the company lost $2.8 million, or 59 cents a share, on revenue of $1.1 million. That compared with a loss of $2.5 million, or 96 cents a share, on revenue of $261,000 for the corresponding 1991 period.
December 24, 1993
I-Flow Corp. said this week it received $4.5 million from an offering of common stock and warrants. I-Flow sold 772,000 units--one warrant and one share each--in a private placement in the United States and 1.5 million units in Europe. The warrant entitles a holder to purchase another share at $3 before December, 1996. The stock closed Monday at $2.0625 on the Nasdaq, down 6.25 cents. I-Flow makes devices for infusing several fluids at once intravenously into patients.
December 27, 2000 |
Lake Forest infusion products maker I-Flow Corp. said Tuesday that a federal agency has rescinded its approval for Medicare payments for the company's outpatient pain-management surgical procedures. I-Flow said in a press release that the Health Care Financing Administration decided to deny payments for its proprietary ON-Q and PainBuster pain-management systems because of "budgetary restrictions" on the agency.
August 2, 1996
I-Flow Corp., which posted a profitable quarter and first six months, said Thursday that it expects a third-quarter loss because of a write-off and expenses totaling $5.6 million. The developer of ambulatory infusion systems said that it will write off $5 million for research and development costs and will incur $600,000 in additional expenses related to its acquisition last month of Block Medical operations.
February 11, 1998
I-Flow Corp. said Tuesday it acquired privately held InfuSystem II Inc. and Venture Medical Inc. for about $2.9 million in stock. Detroit-based InfuSystem, with 1997 revenues of more than $6 million, supplies ambulatory infusion equipment to the oncology and hematology markets. Steve Watkins, president of InfuSystem, will continue as president of the InfuSystem unit of I-Flow.